|Articles|April 22, 2011
Enzymotec Signs Krill Deal with India Pharma Company
Enzymotec Ltd. has signed a long term deal to supply krill oil to Lupin Ltd. (Mumbai, India), a leading pharmaceutical company focusing on non-steroidal anti-inflammatory drugs, bacterial infections, and cardiovascular disease.
Advertisement
Enzymotec Ltd. (Migdal HaEmek, Israel) has signed a long term deal to supply krill oil to Lupin Ltd. (Mumbai, India), a leading pharmaceutical company focusing on non-steroidal anti-inflammatory drugs, bacterial infections, and cardiovascular disease.
Lupin is the world’s fifth largest pharmaceutical company, based on subscriptions, says Enzymotec.
A Krill Oil+ product will launch later this year in Indian markets.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Nutritional Outlook - Supplement, Food & Beverage Manufacturing Trends
1
A New Frontier in Eye Health: Digital Wellness, Bioavailability, and the Eye-Brain Connection
2
Clasado Biosciences Partners with Prokopton SAS to Expand Bimuno GOS Distribution in France
3
Finished Product Clinical Validation Emerges as a Competitive Differentiator in the Supplement Industry
4
Lion’s Mane Ingredient Targets Standardized Erinacine A
5